雅各臣科研制药(02633.HK) 发盈喜，预期截至今年3月底止的2025财年录得来自持续经营业务的溢利较去年同期增加超过40%。
集团表示，来自持续经营业务的年内溢利大幅增加主要归因于专科药物及整体非专利药业务业绩理想，以及新获授权产品和新产品强劲推出所带来的收益贡献。此外，生产设施经营杠杆的提升以及因有效成本控制措施而节省的相应开支，亦推动相关增长。
由于在2023年8月向股东实物分派健倍苗苗(02161.HK) 股份作为特别股息后，公司不再将健倍苗苗及其附属的业绩于财务报表综合入账。因此，预期2025财年权益持有人应占溢利将按年增加超过10%。(sl/j)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.